NRXP - Latest News
NRx Pharmaceuticals, Inc. (NRXP), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $64.5M. Beta to the broader market is 2.19.
The article list below shows the most recent NRXP headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent NRXP Headlines
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
globenewswire.com - Jun 25, 2026
WILMINGTON, Del. , June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
globenewswire.com - Jun 25, 2026
First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from rese
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
businesswire.com - Jun 24, 2026
SAN DIEGO--(BUSINESS WIRE)--Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, have filed a complaint against NRx Pharmaceuticals, I
ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics
prnewswire.com - Jun 23, 2026
SARASOTA, Fla, and BOSTON, June 23, 2026 /PRNewswire/ -- ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company (Nasdaq: NRXP), today ann
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
globenewswire.com - Jun 22, 2026
WILMINGTON, Del. , June 22, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc.
How News Affects NRXP Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track NRXP's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked NRXP news questions
- What is the latest NRXP news headline?
- The most recent NRXP headline (Jun 25, 2026) is "NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the NRXP news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What NRXP news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual NRXP options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.